Traditional treatments do not improve survival outcomes of patients with EGFR-mutated NSCLC who developed LM during EGFR-TKI therapy, and there is still no consensus on the ideal therapeutic strategy that could improve their survival outcomes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.